IXICO Appoints Bram Goorden as New CEO

IXICO Announces Leadership Change

IXICO plc, a prominent AI data analytics company specializing in neuroscience clinical trials, has revealed a significant leadership transition. The company has appointed Bram Goorden as its new Chief Executive Officer, set to take effect on July 1, 2023 1

1

Bram Goorden's Background and Experience

Bram Goorden brings a wealth of experience to his new role at IXICO. He has served as the company's Chief Business Officer since September 2021, demonstrating his familiarity with IXICO's operations and strategic direction. Prior to joining IXICO, Goorden held leadership positions at various life sciences and pharmaceutical companies, including Danone, Nutricia, and Novartis 1

1

Transition Process and Interim Leadership

The appointment of Goorden follows a comprehensive selection process led by IXICO's Board of Directors. In the interim period leading up to July 1, Grant Nash, the company's Chief Financial Officer, will serve as acting CEO. This arrangement ensures a smooth transition of leadership and maintains continuity in the company's operations 2

2

Board's Confidence in the New Leadership

Charles Spicer, IXICO's Chairman, expressed confidence in Goorden's appointment, citing his strong commercial and operational experience in the life sciences sector. The Board believes that Goorden's leadership will be instrumental in driving IXICO's growth and capitalizing on the increasing demand for the company's AI-enabled imaging solutions in clinical trials 1

1

Related Stories

Generative AI Solutions Corp. Appoints Patrick Gray as New CEO Amid Leadership Transition

Firefly Neuroscience Appoints Greg Lipschitz as Executive Chairman, Strengthening AI-Driven Brain Health Solutions

IGC Pharma Advances AI-Driven Alzheimer's Research and Treatment in Q1 2026

Cerence Appoints Former Intel CEO Brian Krzanich as New Chief Executive

Goorden's Vision for IXICO

Upon his appointment, Bram Goorden shared his enthusiasm for leading IXICO into its next phase of growth. He emphasized the company's strong foundation in delivering high-quality services to its clients in the pharmaceutical industry. Goorden expressed his commitment to building on this foundation and expanding IXICO's impact in supporting the development of new therapies for patients with neurological conditions 1

1

Market Response and Future Outlook

The announcement of Goorden's appointment was well-received by the market. IXICO's shares saw a modest increase following the news, reflecting investor confidence in the company's leadership transition. As IXICO continues to innovate in the field of AI-driven neuroscience analytics, industry observers will be closely watching how Goorden's leadership shapes the company's future strategies and market position 2

2